During week 45 (ending 12 November 2017), influenza activity was low across all surveillance systems and RSV activity continues to increase.

**Community influenza surveillance**
- Eight new acute respiratory outbreaks have been reported in the past 7 days. Seven outbreaks were from care homes, where one tested positive for parainfluenza and another for rhinovirus. The remaining outbreak was from a hospital and tested positive for influenza A (not subtyped).

**Overall weekly influenza GP consultation rates across the UK**
- In week 45, the overall weekly influenza-like illness (ILI) consultation rate was 6.4 per 100,000 in England, compared to 5.0 per 100,000 in week 44. This is below the baseline threshold of 13.1 per 100,000 for this season. In the devolved administrations, ILI rates were also below baseline thresholds.
- Through the Syndromic Surveillance systems, GP in hours consultations for influenza-like illness (ILI) were low in week 45 (GP OOH) and there were further small increases in bronchitis/bronchiolitis consultations (GP OOH) and difficulty breathing calls (NHS 111) in infants aged <1 year, in line with recent increases in laboratory reports for respiratory syncytial virus (RSV).

**Influenza-confirmed hospitalisations**
- In week 45, there were seven admissions to ICU/HDU with confirmed influenza (three influenza A(H1N1)pdm09, two influenza A (unknown subtype) and two influenza B) reported across the UK (122/155 Trusts in England) through the USISS mandatory ICU scheme with a rate of 0.02 per 100,000, compared to 0.01 per 100,000 in the previous week.
- In week 45, there were six hospitalised confirmed influenza cases (three influenza A(H1N1)pdm09, one influenza A(H3N2), and two influenza A (unknown subtype)) reported through the USISS sentinel hospital network (16 NHS Trusts across England), with a rate of 0.07 per 100,000 compared to 0.05 per 100,000 in the previous week.
- No laboratory confirmed influenza admissions have been reported from the six Severe Respiratory Failure centres in the UK in week 45.

**All-cause mortality data**
- In week 45 2017, no statistically significant excess all-cause mortality by week of death was seen through the EuroMOMO algorithm in England and in the devolved administrations.

**Microbiological surveillance**
- Five samples tested positive for influenza (one influenza A (unknown subtype), one influenza A (H3), one influenza A (H1N1)pdm09 and two influenza B) through the UK GP sentinel swabbing schemes, with an overall positivity of 7.6% in week 45.
- Twenty-two positive detections were recorded through the DataMart scheme (eight influenza A (H3), seven influenza A (not subtyped), two influenza A (H1N1)pdm09 and five influenza B) with a positivity of 1.5% in week 45. RSV activity continues to increase at 13.3% in week 45 and the highest positivity was seen in <5 year olds at 36.3%.

**Vaccination**
- Up to week 45 2017, in 76.2% of GP practices reporting weekly to Immform, the provisional proportion of people in England who had received the 2017/18 influenza vaccine in targeted groups was: 38.3% in under 65 years in a clinical risk group, 38.9% in pregnant women and 64.7% in 65+ year olds.
- Up to week 45 2017 in 75.3% of GP practices reporting weekly to Immform, the provisional proportion of children in England who had received the 2017/18 influenza vaccine in targeted groups was: 28.8% in 2 year olds and 29.1% in 3 year olds.
- Flu vaccine uptake data on 4 year olds will be collected through the school delivery programme together with uptake for 5-8 year olds and published in the monthly report, to be published on 23 November 2017.

**International situation**
- Globally, influenza activity remained at low levels in the temperate zone of the northern hemisphere. Declining levels of influenza activity were reported in the temperate zone of the southern hemisphere. Worldwide, influenza A(H3N2) and B viruses accounted for the majority of influenza detections.
Eight new acute respiratory outbreaks were reported in the past 7 days.

- **Acute respiratory disease outbreaks**
  - Eight new acute respiratory outbreaks have been reported in the past 7 days. Seven outbreaks were from care homes, where one tested positive for parainfluenza and another for rhinovirus. The remaining outbreak was from a hospital and tested positive for influenza A (not subtyped).
  - Outbreaks should be recorded on HPZone and reported to the local Health Protection Teams and resp cidsc@phe.gov.uk

- **Medical Officers of Schools Association (MOSA) & PHE surveillance scheme**
  - Boarding schools in England within the MOSA network are recruited each season to report various respiratory related illnesses including influenza like illnesses (ILI). For the 2017/18 season, 21 MOSA schools have agreed to participate in the scheme, including a total of 7,575 boarders.
  - The overall ILI rate (all boarders) for week 44 was 4.5 per 1,000 boarders.
  - Since week 40, four outbreaks have been reported from two MOSA schools, with a total of 16 ILI cases identified.
  - If you are a MOSA school and would like to participate in this scheme, please email mosa@phe.gov.uk for more information.

- **FluSurvey**
  - Internet-based surveillance of influenza-like illness in the general population is undertaken through the FluSurvey. A project run jointly by PHE and the London School of Hygiene and Tropical Medicine.
  - The overall ILI rate (all age groups) for week 45 was 30.0 per 1,000 (59/1,967 people reported at least 1 ILI) (Figure 3), with the highest rate seen in the <20 year olds (49.5 per 1,000).
  - If you would like to become a participant of the FluSurvey project please do so by visiting the https://flusurvey.org.uk/en/accounts/register/ website for more information.
In week 45, the overall weekly influenza-like illness (ILI) GP consultation rate is low and is below the baseline threshold in England. In the devolved administrations, ILI rates were low in week 45.

- **GP ILI consultations in the UK**

  **RCGP (England)**
  - The weekly ILI consultation rate through the RCGP surveillance is at 6.4 per 100,000 in week 45 compared to 5.0 per 100,000 in week 44. This is below the baseline threshold (13.1 per 100,000) (Figure 3*). By age group, the highest rates were seen in 15-44 year olds (8.3 per 100,000) and 1-4 year olds (6.6 per 100,000).

  

  *The Moving Epidemic Method (MEM) has been adopted by the European Centre for Disease Prevention and Control to calculate thresholds for GP ILI consultations for the start of influenza activity (based on 10 seasons excluding 2009/10) in a standardised approach across Europe. For MEM intensity threshold values, please visit: https://www.gov.uk/guidance/sources-of-uk-flu-data-influenza-surveillance-in-the-uk#clinical-surveillance-through-primary-care

  **UK**
  - In week 45, overall weekly ILI consultation rates across the countries of the UK were low (Table 1).
  - By age group, the highest rates were seen in the 1-4 in Scotland and Wales (9.7 per 100,000 and 7.2 per 100,000 respectively) and in the 75+ year olds in Northern Ireland (6.7 per 100,000).

  **Table 1: GP ILI consultations in the UK for all ages with MEM thresholds applied**

<table>
<thead>
<tr>
<th>GP ILI consultation rates (all ages)</th>
<th>Week number</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>40</td>
</tr>
<tr>
<td>England (RCGP)</td>
<td>6.6</td>
</tr>
<tr>
<td>Wales</td>
<td>5.7</td>
</tr>
<tr>
<td>Scotland</td>
<td>4.5</td>
</tr>
<tr>
<td>Northern Ireland</td>
<td>3.4</td>
</tr>
</tbody>
</table>

  *The Moving Epidemic Method (MEM) has been adopted by the European Centre for Disease Prevention and Control to calculate thresholds for GP ILI consultations for the start of influenza activity (based on 10 seasons excluding 2009/10), in a standardised approach across Europe. For MEM threshold values for each country, please visit: https://www.gov.uk/guidance/sources-of-uk-flu-data-influenza-surveillance-in-the-uk#clinical-surveillance-through-primary-care

  **GP In Hours Syndromic Surveillance System (England)**
  - The weekly ILI consultation rate through the GP In Hours Syndromic Surveillance system is at 4.7 per 100,000 in week 45 (Figure 5).

  There were further small increases in bronchitis/bronchiolitis consultations (GP OOH) and difficulty breathing calls (NHS 111) in infants aged < 1 year, in line with recent increases in laboratory reports for respiratory syncytial virus (RSV).

  Figure 4 represents a map of GP ILI consultation rates in week 445 across England by upper tier Local Authorities (utLA), with influenza-like illness surveillance MEM thresholds applied.

  **ILI consultation rates presented for each utLA on the map should be interpreted in context of regional and national ILI activity; as MEM thresholds are calculated (based on previous influenza seasons from 2012/13 onwards) separately for each of the nine PHE centres and utLA rates are then compared to Centre-level thresholds only, therefore utLAs with higher background rates than the Centre may appear to have higher ILI activity.**

  - For further information, please see the syndromic surveillance webpage.
In 45, there were seven admission to ICU/HDU with confirmed influenza (three influenza A(H1N1)pdm09, two influenza A(unknown subtype) and two influenza B) reported through the USISS mandatory ICU/HDU surveillance scheme across the UK (122 Trusts). Six hospitalised confirmed influenza cases (three influenza A(H1N1)pdm09, one influenza A(H3N2), and two influenza A(unknown subtype)) were reported through the USISS sentinel hospital network across England (16 Trusts).

- Number of new admissions and fatal confirmed influenza cases in ICU/HDU (USISS mandatory ICU scheme), UK (week 45)

- In week 45, there were seven admissions to ICU/HDU with confirmed influenza (three influenza A(H1N1)pdm09, two influenza A(unknown subtype) and two influenza B) reported across the UK (122/155 Trusts in England) through the USISS mandatory ICU scheme, with a rate of 0.02 per 100,000 (Figures 6 and 7). No deaths were reported to have occurred in week 45.

A total of 25 admissions (five influenza A(H1N1)pdm09, two influenza A(H3N2), ten influenza A(unknown subtype) and eight influenza B) and three confirmed deaths have been reported since week 40 2017.

**Figure 6: Weekly ICU/HDU influenza admission rate per 100,000 trust catchment population, England, since week 40 2017**

*The Moving Epidemic Method (MEM) has been adopted by the European Centre for Disease Prevention and Control to calculate thresholds for ICU/HDU admission rates for the start of influenza activity (based on 6 seasons) in a standardised approach across Europe. For MEM threshold values, please visit: https://www.gov.uk/guidance/sources-flu-data-influenza-surveillance-in-the-uk#disease-severity-and-mortality-data

**Figure 7: Cumulative ICU influenza admissions (USISS mandatory) by age group and flu type, UK, since week 40 2017**

**Figure 8: Weekly hospitalised influenza case rate per 100,000 trust catchment population, England, since week 40 2017**

*The Moving Epidemic Method (MEM) has been adopted by the European Centre for Disease Prevention and Control to calculate thresholds for ICU/HDU infection rates for the start of influenza activity (based on 6 seasons) in a standardised approach across Europe. For MEM threshold values, please visit: https://www.gov.uk/guidance/sources-flu-data-influenza-surveillance-in-the-uk#disease-severity-and-mortality-data

- USISS sentinel weekly hospitalised confirmed influenza cases, England (week 45)

- In week 45, there were six hospitalised confirmed influenza cases (three influenza A(H1N1)pdm09, one influenza A(H3N2), and two influenza A(unknown subtype)) reported through the USISS sentinel hospital network from 16 NHS Trusts across England (Figure 8), a rate of 0.07 per 100,000 compared to 0.05 per 100,000 in the previous week.

A total of 58 hospitalised confirmed influenza admissions (12 influenza A(H1N1)pdm09, 19 influenza A(H3N2), 10 influenza A(unknown subtype) and 17 influenza B) have been reported since week 40 2017.

- USISS Severe Respiratory Failure Centre confirmed influenza admissions, UK (week 45)

- In week 45, there were no laboratory confirmed influenza admissions reported from the six Severe Respiratory Failure (SRF) centres in the UK.
In week 45 2017 in England, no statistically significant excess all-cause mortality by week of death was observed through the EuroMOMO algorithm in England. In the devolved administrations, no significant excess all-cause mortality was observed in week 45 2017.

- **All-cause death registrations, England and Wales**

  - In week 44 2017, an estimated 9,984 all-cause deaths were registered in England and Wales (source: Office for National Statistics). This is an increase compared to the 9,739 estimated death registrations in week 43 2017.

- **Excess all-cause mortality by age group, England, Wales, Scotland and Northern Ireland**

  - In week 45 2017 in England, no excess mortality by week of death above the upper 2 z-score threshold was seen overall, by age group or subnationally, after correcting ONS disaggregate data for reporting delay with the standardised EuroMOMO algorithm (Figure 9). This data is provisional due to the time delay in registration; numbers may vary from week to week.

  - In the devolved administrations, no significant excess mortality above the threshold was observed in week 45 (Table 2).

Table 2: Excess mortality by UK country, for all ages*

<table>
<thead>
<tr>
<th>Country</th>
<th>Excess detected in week 45 2017?</th>
<th>Weeks with excess in 2017/18</th>
</tr>
</thead>
<tbody>
<tr>
<td>England</td>
<td>×</td>
<td>NA</td>
</tr>
<tr>
<td>Wales</td>
<td>×</td>
<td>NA</td>
</tr>
<tr>
<td>Scotland</td>
<td>×</td>
<td>41</td>
</tr>
<tr>
<td>Northern Ireland</td>
<td>×</td>
<td>NA</td>
</tr>
</tbody>
</table>

*Excess mortality is calculated as the observed minus the expected number of deaths in weeks above threshold

In week 45 2017 in England, no excess mortality by week of death above the upper 2 z-score threshold was seen overall, by age group or subnationally, after correcting ONS disaggregate data for reporting delay with the standardised EuroMOMO algorithm (Figure 9). This data is provisional due to the time delay in registration; numbers may vary from week to week.

- In the devolved administrations, no significant excess mortality above the threshold was observed in week 45 (Table 2).

Figure 9: Weekly observed and expected number of all-age all-cause deaths, with the dominant circulating strain influenza A type, England, 2013 to 2017

**Notes:**

- All-cause death registrations, England and Wales: In week 44 2017, an estimated 9,984 all-cause deaths were registered in England and Wales (source: Office for National Statistics). This is an increase compared to the 9,739 estimated death registrations in week 43 2017.

- Excess all-cause mortality by age group, England, Wales, Scotland and Northern Ireland: In week 45 2017 in England, no excess mortality by week of death above the upper 2 z-score threshold was seen overall, by age group or subnationally, after correcting ONS disaggregate data for reporting delay with the standardised EuroMOMO algorithm (Figure 9). This data is provisional due to the time delay in registration; numbers may vary from week to week.

- In the devolved administrations, no significant excess mortality above the threshold was observed in week 45 (Table 2).

- All-cause death registrations, England and Wales: In week 44 2017, an estimated 9,984 all-cause deaths were registered in England and Wales (source: Office for National Statistics). This is an increase compared to the 9,739 estimated death registrations in week 43 2017.

- Excess all-cause mortality by age group, England, Wales, Scotland and Northern Ireland: In week 45 2017 in England, no excess mortality by week of death above the upper 2 z-score threshold was seen overall, by age group or subnationally, after correcting ONS disaggregate data for reporting delay with the standardised EuroMOMO algorithm (Figure 9). This data is provisional due to the time delay in registration; numbers may vary from week to week.

- In the devolved administrations, no significant excess mortality above the threshold was observed in week 45 (Table 2).
In week 45 2017, five samples tested positive for influenza (one influenza A(H3), one influenza A(H1N1)pdm09, one influenza A(unknown subtype) and two influenza B) through the UK GP sentinel schemes, with an overall positivity of 7.6%. Twenty-two positive detections were recorded through the DataMart scheme (eight influenza A(H3), two influenza A(H1N1)pdm09, seven influenza A(unknown subtype) and five influenza B) with a positivity of 1.5% in week 45. RSV activity continues to increase at 13.3% in week 45 and the highest positivity was seen in <5 year olds at 36.3%.

- Sentinel swabbing schemes in England (RCGP) and the Devolved Administrations

In week 45, five samples tested positive for influenza (one influenza A(H3), one influenza A(H1N1)pdm09, one influenza A(unknown subtype) and two influenza B) with an overall positivity of 7.6% compared to 5.9% in week 44 through the UK GP sentinel swabbing schemes (Figure 10).

Since week 40, a total of 23 samples (5 influenza A(H3), 9 influenza (unknown subtype), 1 influenza A(H1N1)pdm09 and 8 influenza B) tested positive for influenza through this scheme.

- Respiratory DataMart System (England)

In week 45 2017, out of the 1,425 respiratory specimens reported through the Respiratory DataMart System, 22 samples (1.5%) were positive for influenza (eight influenza A(H3), seven influenza A(unknown subtype), two influenza A(H1N1)pdm09 and five influenza B) (Figure 11), which is below the MEM threshold for this season of 8.6%. The overall positivity for RSV continued to increase at 13.3% in week 45 compared to 9.6% in week 44. The highest positivity for RSV by age group was seen in the <5 year olds at 36.3% in week 45, an increase from 28.6% in week 44 (Figure 12). Rhinovirus positivity continued to decrease at 16.9% in week 45 compared to 20.4% in week 44. Adenovirus positivity remained stable at 3.6%. Parainfluenza and human metapneumovirus (hMPV) positivity increased slightly in week 45, at 7.5% and 2.4% respectively (Figure 13).

*The Moving Epidemic Method has been adopted by the European Centre for Disease Prevention and Control to calculate thresholds for GP ILI consultations for the start of influenza activity in a standardised approach across Europe. The threshold to indicate a likelihood of influenza community circulation for Datamart % positive as calculated through the Moving Epidemic Method is 8.6% in 2017/18.*
• Virus characterisation
PHE characterises the properties of influenza viruses through one or more tests, including genome sequencing (genetic analysis) and haemagglutination inhibition (HI) assays (antigenic analysis). These data are used to compare how similar the currently circulating influenza viruses are to the strains included in seasonal influenza vaccines, and to monitor for changes in circulating influenza viruses. The interpretation of genetic and antigenic data sources is complex due to a number of factors, for example, not all viruses can be cultivated in sufficient quantity for antigenic characterisation, so that viruses with sequence information may not be able to be antigenically characterised as well. Occasionally, this can lead to a biased view of the properties of circulating viruses, as the viruses which can be recovered and analysed antigenically, may not be fully representative of majority variants, and genetic characterisation data does not always predict the antigenic characterisation.

The PHE Respiratory Virus Unit has characterised 41 influenza viruses detected since late summer (Table 3). Of the 7 A(H1N1)pdm09 influenza viruses that have been characterised, all belong in the genetic subgroup 6B.1, which was the predominant genetic subgroup in the 2016/17 season. The two viruses antigenically analysed are similar to the A/Michigan/45/2015 Northern Hemisphere 2017/18 (H1N1)pdm09 vaccine strain.

Genetic characterisation of 23 A(H3N2) influenza viruses detected since late summer, showed that they all belong to genetic subclade 3C.2a, with 14 belonging to a cluster within this genetic subclade designated as 3C.2a1. The Northern Hemisphere 2017/18 influenza A(H3N2) vaccine strain A/HongKong/4801/2014 belongs in genetic subclade 3C.2a.

Eleven influenza B viruses have been analysed; 8 were characterised as belonging to the B/Yamagata/16/88-lineage and 3 belonging to the B/Victoria/2/1987-lineage. Of the influenza B viruses antigenically characterised, the B/Victoria/2/87-lineage viruses were antigenically similar to B/Brisbane/60/2008, the influenza B/Victoria-lineage component of 2017/18 Northern Hemisphere trivalent and quadrivalent vaccines. B/Yamagata/16/88-lineage viruses were antigenically similar to B/Phuket/3073/2013, the influenza B/Yamagata-lineage component of 2016/17 Northern Hemisphere quadrivalent vaccine.

Table 3: Viruses characterised by PHE Reference Laboratory, 2017/18

<table>
<thead>
<tr>
<th>Virus type/subtype</th>
<th>No. viruses characterised</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Genetic and antigenic</td>
</tr>
<tr>
<td>A(H1N1)pdm09</td>
<td>2</td>
</tr>
<tr>
<td>A(H3N2)</td>
<td>0</td>
</tr>
<tr>
<td>B/Yamagata-lineage</td>
<td>2</td>
</tr>
<tr>
<td>B/Victoria-lineage</td>
<td>3</td>
</tr>
</tbody>
</table>

• Antiviral susceptibility
Influenza positive samples are screened for mutations in the virus neuraminidase gene known to confer oseltamivir and/or zanamivir resistance. Additionally, testing of influenza A (H1N1)pdm09, A(H3N2), and influenza B virus isolates for neuraminidase inhibitor susceptibility (oseltamivir and zanamivir) is performed at PHE-RVU using a functional assay. The data summarized below combine the results of both testing methods. The samples tested are routinely obtained for surveillance purposes, but diagnostic testing of patients suspected to be infected with neuraminidase inhibitor-resistant virus is also performed.

During the current 2017/18 season so far, nine influenza A(H3N2) have been tested for oseltamivir susceptibility; seven are susceptible. Two viruses have a deletion in the neuraminidase gene, at amino acids 245 to 248. This deletion reduces susceptibility to oseltamivir, but is not likely to reduce zanamivir susceptibility. One of these two oseltamivir resistant viruses has a E119V amino acid substitution in addition, also affecting oseltamivir susceptibility but not zanamivir. Three of the A(H3N2) viruses were also tested for zanamivir susceptibility with all being fully susceptible. Eleven influenza A(H1N1)pdm09 virus have been tested for oseltamivir susceptibility and all were fully susceptible. Two of the 11 influenza A(H1N1)pdm09 virus was also tested for zanamivir susceptibility and was fully susceptible. Three influenza B viruses have been tested for oseltamivir susceptibility and were fully susceptible.

• Antimicrobial susceptibility
Table 4: Antimicrobial susceptibility surveillance in lower respiratory tract isolates, 12 weeks up to 12 November 2017, E&W

<table>
<thead>
<tr>
<th>Organism</th>
<th>Antibiotic</th>
<th>Specimens tested (N)</th>
<th>Specimens susceptible (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>S. pneumoniae</td>
<td>Penicillin</td>
<td>357</td>
<td>86</td>
</tr>
<tr>
<td></td>
<td>Macrolides</td>
<td>396</td>
<td>80</td>
</tr>
<tr>
<td></td>
<td>Tetracycline</td>
<td>382</td>
<td>82</td>
</tr>
<tr>
<td></td>
<td>Aminocillin</td>
<td>1297</td>
<td>69</td>
</tr>
<tr>
<td>H. influenza</td>
<td>Co-amoxicillin</td>
<td>1310</td>
<td>87</td>
</tr>
<tr>
<td></td>
<td>Macrolides</td>
<td>471</td>
<td>12</td>
</tr>
<tr>
<td></td>
<td>Tetracycline</td>
<td>1313</td>
<td>98</td>
</tr>
<tr>
<td>S. aureus</td>
<td>Methicillin</td>
<td>605</td>
<td>91</td>
</tr>
<tr>
<td></td>
<td>Macrolides</td>
<td>656</td>
<td>68</td>
</tr>
<tr>
<td>MRSA</td>
<td>Clindamycin</td>
<td>37</td>
<td>35</td>
</tr>
<tr>
<td></td>
<td>Tetracycline</td>
<td>54</td>
<td>83</td>
</tr>
<tr>
<td>MSSA</td>
<td>Clindamycin</td>
<td>320</td>
<td>80</td>
</tr>
<tr>
<td></td>
<td>Tetracycline</td>
<td>519</td>
<td>95</td>
</tr>
</tbody>
</table>

*Macrolides = erythromycin, azithromycin and clarithromycin
- Up to week 45 2017 in 76.2% of GP practices reporting weekly to Immform, the provisional proportion of people in England who had received the 2017/18 influenza vaccine in targeted groups was as follows (Figure 14):
  - 38.3% in under 65 years in a clinical risk group
  - 38.9% in pregnant women
  - 64.7% in 65+ year olds

- In 2017/18, all two- and three-year-olds continue to be eligible for flu vaccination, through their GPs. Up to week 45 2017 in 75.3% of GP practices reporting weekly to Immform, the provisional proportion of children in England who had received the 2017/18 influenza vaccine in targeted groups was as follows (Figure 15):
  - 28.8% in 2 year olds
  - 29.1% in 3 year olds

In addition, the programme has been extended to children of school years Reception (4 year olds), 1, 2, 3 and 4 age. The data for the school programme, including 4 year olds, will be included in the monthly report to be published on 23 November 2017.
Influenza activity remained at low levels in the temperate zone of the northern hemisphere. Declining levels of influenza activity were reported in the temperate zone of the southern hemisphere. Worldwide, influenza A(H3N2) and B viruses accounted for the majority of influenza detections.

- **Europe** updated on 10 November 2017 (Joint ECDC-WHO Influenza weekly update)

In week 44/2017, low intensity of influenza activity was reported by all of the 42 reporting countries. No geographic spread was reported by 26 of the 43 reporting countries, while sporadic cases or local geographic spread was reported by 17 countries.

For week 44/2017, 8 (1%) of 643 sentinel specimens tested positive for influenza viruses: 2 unsubtype A viruses, 1 A(H3N2), 1 B/Yamagata lineage and 4 B viruses not ascribed to a lineage.

Since week 40/2017, 5 countries have reported laboratory-confirmed hospitalized influenza cases in intensive care units (ICU) or other wards: 22 cases in ICU (18 in the United Kingdom, 3 Spain and 1 in the Czech Republic) and 29 in other wards (18 in Ireland, 7 in Denmark, 2 each in the Czech Republic and Spain). Of 22 cases in ICU, 16 (73%) were infected with type A viruses (4 A(H1N1)pdm09, 3 A(H3N2), 9 A un subtype) and 6 (27%) with type B viruses. A similar picture was observed in other wards: of 29 patients, 21 (72%) were infected with influenza A (10 A un subtype, 5 A(H1N1)pdm09, 6 A(H3N2)) and 8 (28%) with influenza B viruses.

For week 44/2017, 138 specimens from non-sentinel sources (such as hospitals, schools, non-sentinel primary care facilities, nursing homes and other institutions) tested positive for influenza viruses. Of these, 74% were type A and 26% type B viruses. The majority of viruses from non-sentinel specimens were not subtype or assigned to a lineage.

For week 44/2017, data from the 14 countries or regions reporting to the EuroMOMO project indicated all-cause mortality at expected levels for this time of the year.

- **United States of America** updated on 10 November 2017 (Centre for Disease Control report)

During week 44, influenza activity was low in the United States.

The most frequently identified influenza virus type reported by public health laboratories during week 44 was influenza A. The percentage of respiratory specimens testing positive for influenza in clinical laboratories is low.

The proportion of deaths attributed to pneumonia and influenza (P&I) was below the system-specific epidemic threshold in the National Center for Health Statistics (NCHS) Mortality Surveillance System.

The proportion of outpatient visits for influenza-like illness (ILI) was 1.8%, which is below the national baseline of 2.2%.

- **Canada** updated on 10 November 2017 (Public Health Agency report)

Overall, influenza activity continues to increase but remains below the seasonal threshold across the country in week 44.

The percentage of laboratory tests positive for influenza remains higher for this time of year compared to previous seasons. The majority of influenza detections continue to be A(H3N2).

In week 44, 1.6% of visits to healthcare professionals were due to influenza-like illness; a slight decrease compared to the previous week, but remains slightly above the 5-year average.

In week 44, 15 influenza-associated hospitalizations were reported by participating provinces and territories.

To date this season, 159 influenza-associated hospitalizations have been reported, 93% of which were associated with influenza A, and 115 cases (72%) were in adults 65 years of age or older. The number of cases is considerably elevated relative to this period in the previous two seasons. Eight ICU admissions and eight deaths have been reported.

- **Global influenza update** updated on 13 November 2017 (WHO website)

Influenza activity remained at low levels in the temperate zone of the northern hemisphere. Declining levels of influenza activity were reported in the temperate zone of the southern hemisphere. Worldwide, influenza A(H3N2) and B viruses accounted for the majority of influenza detections.
In North America, overall influenza activity increased slightly but remained low, with detections of predominantly influenza A(H3N2) and B viruses in the past weeks.

In Europe, influenza activity remained low, with detections of predominantly influenza A(H3N2) and B viruses.

In Western Asia, influenza activity was low in general. In Qatar, influenza activity remained high with all seasonal subtypes co-circulating. In Central Asia, influenza like illness (ILI) and severe acute respiratory infection (SARI) indicators appeared to increase in Kazakhstan, Tajikistan and Uzbekistan.

In East Asia, influenza activity remained low in general. In Northern China, influenza A(H3N2) detections increased slightly in recent weeks.

In South East Asia, influenza activity continued to decrease, with influenza A(H3N2) and B viruses most frequently detected.

In Southern Asia, influenza activity remained low in general. In India, influenza A(H1N1)pdm09 and A(H3N2) detections decreased in recent weeks.

In Northern Africa, there were no reports during the reporting period. In Western and Middle Africa, influenza detections continued to be reported, with all seasonal influenza subtypes present in the region. In Eastern Africa, little to no influenza activity was reported.

In the Caribbean and Central American countries, respiratory illness indicators and influenza activity remained low in general but respiratory syncytial virus (RSV) activity remained high in several countries.

In the tropical countries of South America, influenza and RSV activity remained at low levels.

In the temperate zone of the Southern Hemisphere, influenza activity appeared to have decreased overall.

Between 16 October 2017 and 29 October 2017, 4,088 specimens tested positive for influenza viruses through the WHO GISRS laboratories, of which 2,954 (72.3%) were typed as influenza A and 1,134 (27.7%) as influenza B. Of the sub-typed influenza A viruses, 318 (13.8%) were influenza A(H1N1)pdm09 and 1,985 (86.2%) were influenza A(H3N2). Of the characterized B viruses, 485 (81.1%) belonged to the B-Yamagata lineage and 113 (18.9%) to the B-Victoria lineage.

- **Avian Influenza** latest update on 30 October 2017 (WHO website)

**Influenza A(H5) viruses**
Since the last update on 27 September 2017, one new laboratory-confirmed human case of influenza A(H5N1) virus infection was reported to WHO from Indonesia.

Since 2003, a total of 860 laboratory-confirmed cases of human infection with avian influenza A(H5N1) virus, including 454 deaths, have been reported to WHO from 16 countries.

Influenza A(H5) subtype viruses have the potential to cause disease in humans and thus far, no human cases, other than those with influenza A(H5N1) and A(H5N6) viruses, have been reported to WHO.

According to reports received by the World Organisation for Animal Health (OIE), various influenza A(H5) subtypes continue to be detected in birds in Africa, Europe and Asia.

**Influenza A(H7N9)**
Since the last update on 27 September 2017, no new laboratory-confirmed human cases of influenza A(H7N9) virus infection were reported to WHO.

Since 2013, a total of 1,564 laboratory-confirmed cases of human infection with avian influenza A(H7N9) viruses, including at least 612 deaths, have been reported to WHO.

**Influenza A(H1N2) variant viruses**
Between 28 September and 30 October 2017, one new laboratory-confirmed human infection with influenza A(H1N2)v virus was detected in the state of Ohio in the United States (U.S).
Since 2005, 12 cases of A(H1N2)v influenza virus infections have been reported to the U.S. Centers for Disease Control and Prevention (CDC).

**Influenza A(H3N2) variant viruses**
Since 27 September 2017, 41 human infections with influenza A(H3N2)v viruses were detected in the U.S. in several states. Characterization of the viruses from these cases indicates they are similar to A(H3N2)v viruses previously detected and similar to the existing candidate vaccine virus. Since reporting of novel influenza A viruses became nationally notifiable in 2005, 462 human infections with influenza A(H3N2)v viruses have been reported to the U.S. CDC and 59 of these occurred in 2017.

- **Middle East respiratory syndrome coronavirus (MERS-CoV)** latest update on 15 November 2017

  Up to 15 November 2017, a total of four cases of Middle East respiratory syndrome coronavirus, MERS-CoV, (two imported and two linked cases) have been confirmed in the UK. On-going surveillance has identified 1,089 suspect cases in the UK that have been investigated for MERS-CoV and tested negative.

  On 1 November 2017, the International Health Regulations (2005) national focal point of Oman reported one case of Middle East respiratory syndrome coronavirus (MERS-CoV) infection. Prior to this case, the most recent case of MERS-CoV from Oman was reported on 30 August 2017.

  Between 27 September and 31 October 2017, the National IHR Focal Point of the Kingdom of Saudi Arabia reported 12 additional cases of Middle East respiratory syndrome coronavirus (MERS-CoV) infection, including two deaths. Additionally, one death from a previously reported case was reported to WHO.

  Globally, since September 2012, WHO has been notified of 2,102 laboratory-confirmed cases of infection with MERS-CoV, including at least 733 related deaths. Further information on management and guidance of possible cases is available online. The latest ECDC MERS-CoV risk assessment can be found here, where it is highlighted that risk of widespread transmission of MERS-CoV remains low.

**Acknowledgements**

This report was prepared by the Influenza section, Respiratory Diseases Department, Centre for Infectious Disease Surveillance and Control, Public Health England. We are grateful to all who provided data for this report including the RCGP Research and Surveillance Centre, the PHE Real-time Syndromic Surveillance team, the PHE Respiratory Virus Unit, the PHE Modelling and Statistics unit, the PHE Dept. of Healthcare Associated Infection & Antimicrobial Resistance, PHE regional microbiology laboratories, Office for National Statistics, the Department of Health, Health Protection Scotland, National Public Health Service (Wales), the Public Health Agency Northern Ireland, the Northern Ireland Statistics and Research Agency, QSurveillance® and EMIS and EMIS practices contributing to the QSurveillance® database.

**Related links**

**Sources of flu data**
- Clinical surveillance through primary care in the UK
- Outbreak reporting
- FluSurvey
- MOSA
- Real time syndromic surveillance
- MEM threshold methodology paper and UK pilot paper

**Disease severity and mortality data**
- USISS system
- EuroMOMO mortality project

**Vaccination**
- Seasonal influenza vaccine programme (Department of Health Book)
- Childhood flu programme information for healthcare practitioners (Public Health England)
- 2017/18 Northern Hemisphere seasonal influenza vaccine recommendations (WHO)